Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2017 | 1 |
2020 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity.
Cell Discov. 2020 Jul 28;6(1):49. doi: 10.1038/s41421-020-0181-z. eCollection 2020.
Cell Discov. 2020.
PMID: 32793389
Free PMC article.
No abstract available.
Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets.
Vann KR, Pal D, Morales GA, Burgoyne AM, Durden DL, Kutateladze TG.
Vann KR, et al.
Sci Rep. 2020 Jul 21;10(1):12027. doi: 10.1038/s41598-020-68964-6.
Sci Rep. 2020.
PMID: 32694708
Free PMC article.
Item in Clipboard
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG.
Andrews FH, et al.
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1072-E1080. doi: 10.1073/pnas.1613091114. Epub 2017 Jan 30.
Proc Natl Acad Sci U S A. 2017.
PMID: 28137841
Free PMC article.
Item in Clipboard
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
Singh AR, et al.
Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5.
Mol Cancer Ther. 2016.
PMID: 27496136
Free PMC article.
Item in Clipboard
Cite
Cite